Back to News
Market Impact: 0.2
Wall Street Analysts Predict a 77.61% Upside in Zenas BioPharma, Inc. (ZBIO): Here's What You Should Know
Source: zacks.com
Analyst InsightsAnalyst Estimates
Analysts’ mean price target for Zenas BioPharma (ZBIO) implies 77.6% upside. The article cautions that this price-target metric has not proved reasonably effective, while noting that strong analyst agreement in raising earnings estimates indicates potential upside.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
ZBIO0.45
More News
- SpaceX bear flips to big bull because of AI business. Analyst now sees 70% gain
- Williams Trading cuts Deckers Outdoor stock price target on weak DTC trends
- Jefferies raises Zymeworks stock price target on Roche deal
- Truist raises United Rentals stock price target on strong margins
- Century Casinos receives Nasdaq notice for minimum market value deficiency
- GM stock analysis: cheap valuation meets falling estimates after earnings drop